Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

1.

Aberrant and alternative splicing in skeletal system disease.

Fan X, Tang L.

Gene. 2013 Oct 1;528(1):21-6. doi: 10.1016/j.gene.2013.06.027. Epub 2013 Jun 23. Review.

PMID:
23800666
2.

[Wnt signaling molecules related to osteoporosis].

Kubota T, Ozono K.

Clin Calcium. 2013 Jun;23(6):855-60. doi: CliCa1306855860. Review. Japanese.

PMID:
23719498
3.

WNT signaling in bone homeostasis and disease: from human mutations to treatments.

Baron R, Kneissel M.

Nat Med. 2013 Feb;19(2):179-92. doi: 10.1038/nm.3074. Epub 2013 Feb 6. Review.

PMID:
23389618
4.

The importance of the gastrointestinal tract in the control of bone mass accrual.

Karsenty G, Gershon MD.

Gastroenterology. 2011 Aug;141(2):439-42. doi: 10.1053/j.gastro.2011.06.011. Epub 2011 Jun 17. Review.

PMID:
21699800
5.

Regulation of bone mass by serotonin: molecular biology and therapeutic implications.

Karsenty G, Yadav VK.

Annu Rev Med. 2011;62:323-31. doi: 10.1146/annurev-med-090710-133426. Review.

PMID:
21073335
6.

[Cytokines in bone diseases. Wnt signaling and osteoporosis-pseudoglioma syndrome].

Ozono K.

Clin Calcium. 2010 Oct;20(10):1520-5. doi: CliCa101015201525. Review. Japanese.

PMID:
20890034
7.

Lrp5 and bone formation : A serotonin-dependent pathway.

Yadav VK, Ducy P.

Ann N Y Acad Sci. 2010 Mar;1192:103-9. doi: 10.1111/j.1749-6632.2009.05312.x. Review.

PMID:
20392224
8.

The role of the Wnt signaling pathway in osteoblast commitment and differentiation.

Yavropoulou MP, Yovos JG.

Hormones (Athens). 2007 Oct-Dec;6(4):279-94. Review.

9.

The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes.

Balemans W, Van Hul W.

Endocrinology. 2007 Jun;148(6):2622-9. Epub 2007 Mar 29. Review.

PMID:
17395706
10.

Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton.

Baron R, Rawadi G.

Endocrinology. 2007 Jun;148(6):2635-43. Epub 2007 Mar 29. Review.

PMID:
17395698
11.

Wnt signaling: a key regulator of bone mass.

Baron R, Rawadi G, Roman-Roman S.

Curr Top Dev Biol. 2006;76:103-27. Review.

PMID:
17118265
12.

Wnt signaling and osteoblastogenesis.

Bodine PV, Komm BS.

Rev Endocr Metab Disord. 2006 Jun;7(1-2):33-9. Review.

PMID:
16960757
13.

[Wnt-beta-catenin signaling in bone metabolism].

Urano T.

Clin Calcium. 2006 Jan;16(1):54-60. Review. Japanese.

PMID:
16397351
14.

[Systemic bone diseases; clues for the pathogenetic mechanism of osteoporosis].

Tanaka H.

Clin Calcium. 2005 May;15(5):776-82. Review. Japanese.

PMID:
15876739
15.

LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.

Levasseur R, Lacombe D, de Vernejoul MC.

Joint Bone Spine. 2005 May;72(3):207-14. Review.

PMID:
15850991
16.
17.

[Genetic background of osteoporosis].

Takács I, Lakatos P.

Orv Hetil. 2003 Jul 27;144(30):1467-72. Review. Hungarian.

PMID:
14569676
18.

Modern approach to children with osteogenesis imperfecta.

Zeitlin L, Fassier F, Glorieux FH.

J Pediatr Orthop B. 2003 Mar;12(2):77-87. Review.

PMID:
12584489
19.

Genetic control of susceptibility to osteoporosis.

Ralston SH.

J Clin Endocrinol Metab. 2002 Jun;87(6):2460-6. Review.

PMID:
12050200
20.

[Osteoporosis-pseudoglioma syndrome].

Narahara K.

Ryoikibetsu Shokogun Shirizu. 2001;(34 Pt 2):437-8. Review. Japanese. No abstract available.

PMID:
11528824
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk